Elanco Animal Health (ELAN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$5.0B

Revenue (quarter)

$1.4B

Revenue growth (year over year)

+10.23%

Gross profit (trailing twelve months)

$2.8B

Gross margin

55.36%

Net income (trailing twelve months)

−$199.0M

Net income (quarter)

$54.0M

Net income growth (year over year)

+390.91%

Net margin

−3.96%

Return on equity

−2.98%

EPS (trailing twelve months)

−$0.41

Book value per share

$13.19

P/E (trailing twelve months)

—

Price to book

1.70

Debt to assets

51.42%

Payout ratio

—

Dividend yield

—

Company profile

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.

• Is Elanco Animal Health (ELAN) profitable?

  No. Elanco Animal Health reported a net loss of $199.0M over the trailing twelve months.

• How much revenue does Elanco Animal Health (ELAN) make?

  Elanco Animal Health generated $5.0B in revenue over the trailing twelve months, up 10.23% year over year.

• How do I buy stock in Elanco Animal Health (ELAN)?

  ELAN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.